The effect of incretins on potentiating insulin secretion is clinically used for the treatment of type 2 diabetes, such as GLP-1 analogues and DPP4 inhibitors which inhibit GLP-1 inactivating enzyme, DPP4 [17]. Here, INS is linked to type 2 diabetes mellitus.